Hi-Ground





The following results are from samples submitted to CheQpoint between the dates of 19th April 2024 to 7th June 2024. The total number of samples submitted was 32. The total number of samples qualitatively analysed was 23.

Table 1: Qualitative results of submitted samples.

| Expected Drug Type | Samples Submitted (n, %) | Expected Drug Detected (n) | Notes on unexpected/inconclusive results | Expected Carrier Oil | Carrier Oil Detected |
|---------------------------------------|--------------------------------|----------------------------------|---|----------------------|----------------------|
| Injectable | | | | | |
| Testosterone Propionate | 1 (4.3) | 1 | | Not Provided = 1 | MCT = 1 |
| Testosterone Cypionate | 1 (4.3) | 1 | | Not Provided = 1 | MCT = 1 |
| Testosterone Enanthate | 4 (17.4) | 3 | Testosterone Cypionate was detected in 1. | GSO = 1 | GSO = 1 |
| | | | | Not Provided = 3 | MCT = 3 |
| Methenolone Enanthate [Primobolan] | 1(4.3) | 1 | | Not Provided = 1 | MCT = 1 |
| Drostanolone Enanthate [Masteron] | 3 (13.0) | 3 | | GSO = 1 | GSO = 1 |
| | | | | MCT = 1 | MCT = 1 |
| | | | | Not Provided = 1 | MCT = 1 |
| Nandrolone Phenylpropionate [NPP] | 3 (13.0) | 3 | | MCT = 2 | MCT =2 |
| | | | | Not Provided = 1 | MCT = 1 |

Hi-Ground



QuIVAA

| Nandrolone Decanoate [Deca] | 1(4.3) | 1 | | Not Provided = 1 | MCT = 1 |
|-----------------------------|-----------|----------|--|------------------|---------|
| Trenbolone Enanthate | 4 (17.4) | 4 | | GSO = 1 | GSO = 1 |
| | | | | Not Provided = 3 | GSO = 3 |
| Trestolone no ester [MENT] | 1 (4.3) | 0 | Trestolone Acetate | Not Provided = 1 | MCT = 1 |
| Oral | | | | | |
| Mesterolone [Proviron] | 1(4.3) | 1 | | | |
| Oxandrolone [Anavar] | 2 (8.7) | 1 | 1 sample = Stanozolol [Winstrol] detected. 1 sample = Testosterone and oxandrolone were detected. | | |
| Stanozolol [Winstrol] | 1(4.3) | 1 | | | |
| TOTAL | 23 (100%) | 20 (87%) | | | |

*MCT = Medium Chain Triglycerides oil

*GSO = Grape Seed Oil

<u>Footnotes:</u> Oxandrolone, stanozolol, and testosterone are all anabolic-androgenic steroids but differ in their properties. Oxandrolone has a half-life of 9-10 hours and is known for its anabolic effects with less hepatic strain (compared to other C17α-alkylated AASs, for example, stanozolol) and androgenic activity than, for example, testosterone [1,2]. The presence of stanozolol and testosterone indicates a shift towards compounds with potentially higher hepatic strain and androgenic effects but varying anabolic properties. Out of the four samples submitted as testosterone enanthate (17.4%), three matched the expected drug. In one sample, testosterone cypionate, which has a slightly shorter half-life than enanthate [3], was detected instead.

[1] Orr, R., & Singh, M. F. (2004). The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs, 64, 725-750.

[2] Kuhn, C. M. (2002). Anabolic steroids. Recent progress in hormone research, 57, 411-434.

[3] Turza, A., Pascuta, P., Mare, L., Borodi, G., & Popescu, V. (2023). Structural insights and intermolecular energy for some medium and long-chain testosterone esters. *Molecules, 28*(7), 3097.

The following results are from samples submitted to CheQpoint between the dates of 19th April 2024 to 7th June 2024. The total number of samples submitted was 32. The total number of samples quantitatively analysed was 1.

Table 2: Quantitative results of submitted samples.

| Expected Drug Type | Expected Concentration | Detected Concentration |
|--------------------|------------------------|------------------------|
|--------------------|------------------------|------------------------|

Hi-Ground





Testosterone Propionate

100mg/mL

<u>Footnotes:</u> We were able to do this for 1 sample thus far due as we build our reference standard library. As we build this library we will be able to 'back-date' the quantitative analyses when possible.